文献速递淋巴瘤造血干细胞移植与细胞治疗

串联CD19/CD20 CAR-T治疗难治/复发性B细胞淋巴瘤的长期活性:单臂1-2期试验

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
PubMed 文献 · Leukemia · 2021-07-16

该开放标签单臂1/2期试验纳入87例难治/复发性非霍奇金淋巴瘤患者,其中58例为侵袭性弥漫大B细胞淋巴瘤,24例肿瘤负荷高,接受0.5×10^6-8×10^6 TanCAR7 T细胞/kg输注。最佳总缓解率为78%(95%CI 68-86),中位随访27.7个月,中位无进展生存期为27.6个月(95%CI 11-未达到)。细胞因子释放综合征发生61例(70%),3级及以上占10%;3级CAR-T相关脑病综合征仅2例(2%)。

要点

  • TanCAR7 T细胞在r/rNHL中最佳总缓解率达78%,各预后亚组一致。
  • 中位无进展生存期27.6个月,观察到长期缓解。
  • 安全性以细胞因子释放综合征为主,3级及以上CRES仅2%。

核心结论

  • TanCAR7 T细胞在难治/复发性非霍奇金淋巴瘤中可诱导长期缓解,安全性包括CRS但CRES少见。

研究设计与样本

  • 开放标签、单臂1/2期试验,纳入87例难治/复发性非霍奇金淋巴瘤患者。
  • 其中58例为侵袭性弥漫大B细胞淋巴瘤,24例肿瘤负荷高。
  • 清淋化疗后输注0.5×10^6-8×10^6 TanCAR7 T细胞/kg体重。

主要发现

  • 最佳总缓解率为78%(95%CI 68-86),各预后亚组缓解率一致。
  • 中位随访27.7个月,中位无进展生存期为27.6个月(95%CI 11-未达到)。
  • 细胞因子释放综合征发生61例(70%),其中60%为1-2级,10%为3级及以上。
  • 3级CAR-T相关脑病综合征发生2例(2%)。
  • 2例死于治疗相关严重肺部感染,1例死于输注后1-3个月内CRS相关肺损伤。

临床怎么用

  • TanCAR7 T细胞可作为难治/复发性B细胞淋巴瘤的潜在治疗选择,需监测CRS和CRES。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increasing the remission rate and reducing the recurrence rate can improve the clinical efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non-Hodgkin lymphoma (r/rNHL). In this open-label, single-arm phase I/II trial, 87 patients with r/rNHL, including 58 patients with aggressive diffuse large B-cell lymphoma and 24 with high tumour burden, received an infusion at doses of 0.5 × 106-8 × 106 TanCAR7 T cells per kilogram of body weight after conditioning chemotherapy. The best overall response rate was 78% (95% confidence interval [CI], 68-86); response rates were consistent across prognostic subgroups. The median follow-up was 27.7 months. The median progression-free survival was 27.6 months (95% CI, 11 to not reached). Cytokine release syndrome (CRS) occurred in 61 patients (70%) with 60% of cases being grade 1 or 2 and 10% being grade 3 or greater. Grade 3 CAR T cell-related encephalopathy syndrome (CRES) occurred in 2 patients (2%). Two patients died from treatment-associated severe pulmonary infection, and one died from CRS-related pulmonary injury between 1 and 3 months post infusion. Long-term remissions were observed following the use of TanCAR7 T cells in r/rNHL with a safety profile that included CRS but few cases of CRES.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Wang Y, Liu Y, et al. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial. Leukemia. 2021. PMID: 34272481. doi:10.1038/s41375-021-01345-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。